Psoriasiform cutaneous eruptions induced by cetamolol hydrochloride.

  title={Psoriasiform cutaneous eruptions induced by cetamolol hydrochloride.},
  author={W. White and P. Schulman and E. J. McCabe},
  journal={Archives of dermatology},
  volume={122 8},
To the Editor.— Psoriasiform eruptions of the skin are recognized as one of the adverse effects of practolol and other β-adrenergic blocking agents. 1-3 With practolol, the cutaneous syndromes have occurred in association with ocular lesions, 3 sclerosing peritonitis, 4 and systemic lupus erythematosus. 5 Voorhees recently suggested that psoriasis may be precipitated or exacerbated in a third of patients with psoriasis treated with oral propranolol hydrochloride. 6 Cetamolol hydrochloride is a… Expand
Drug-Induced Psoriasis
This review focuses on the most common causative agents for drug-induced, drug-triggered, or drug-aggravated psoriasis, such as ß-blockers, lithium, synthetic antimalarial drugs, nonsteroidal anti-inflammatory agents, and tetracyclines. Expand
Terbinafine therapy may be associated with the development of psoriasis de novo or its exacerbation: four case reports and a review of drug-induced psoriasis.
In all patients the psoriasis cleared or lessened after discontinuation of terbinafine and institution of antipsoriatic therapy, and the development ofPsoriasis in four patients who took oral terbINAfine was described. Expand
The role of drugs in the induction and/or exacerbation of psoriasis
This review focuses on the most common causative agents for drug‐induced, drug‐triggered, or drug‐aggravated psoriasis, such as β‐blockers, lithium, synthetic antimalarial drugs, nonsteroidal anti‐inflammatory agents, and tetracyclines, and the mechanisms of action of these drugs in the pathogenesis of Psoriasis. Expand
A Review of Drugs that Induce or Exacerbate Psoriasis
Characterizing drugs that induce or exacerbate psoriasis by latency and type of psoriatic eruption can help guide clinical reasoning and help astute physicians recognize and change their management plans accordingly. Expand
Beta-blocking drugs and psoriasis. A review of cutaneous side effects and retrospective analysis of their effects on psoriasis.
Dermatologic manifestations of beta-blockers are reviewed in conjunction with their more liberal use and beta-Blockers may worsen psoriasis and should be carefully evaluated in the management of these patients. Expand
Drugs in exacerbation and provocation of psoriasis.
As an allergy, it was sensitive to almost everything: chocolate, potato chips, starch, sugar, frying grease, nervous excitement, dryness, darkness, pressure, enclosure, the temperate climate—allergic, in fact, to life itself. Expand
β-Adrenoceptor antagonists and antianginal drugs
The chapter compares pharmacologic properties of newer and older agents and presents it in the form of a table to help patients decide whether to take the drug or not. Expand
Cardiovascular risk and psoriasis: beyond the traditional risk factors.
An interdisciplinary approach is needed to find the necessary steps beyond classic risk reduction and detection of early cardiovascular disease in patients with psoriasis, as well as to develop a cardiovascular disease preventive regimen. Expand
Beta Adrenergic Receptor Blockers (Class II Antiarrhythmics)
Beta-blockers are classified into two major subgroups as cardioselective (β1) (acebutolol, atenolol) and noncardioselectedive ( β1+β2) blockers (propranolol, nadolol), and α and β receptor blocking activities such as labetalol and carvedilol. Expand


Cutaneous reactions to propranolol (Inderal).
Six patients wit psoriasiform cutaneous eruptions that developed during long-term therapy with propranolol (Inderal) have been studied, and it is recommended that all patients receiving beta-blocking drugs should be examined carefully for similar adverse reactions. Expand
Systemic Lupus Erythematosus Syndrome Induced by Practolol
Three patients with angina pectoris treated with practolol in varying doses developed a syndrome of arthralgia, particularly of the small joints of the hands, rash, fever, a raised E.S.R., andExpand
Cutaneous and Ocular Reactions to Practolol
A total of 21 patients suffering from drug-induced rashes from practolol have been seen over the past two years, with the morphological appearances of the rash resembling those of eczema, lupus ery thematosus, lichen planus, and a highly characteristic toxic erythematous psoriasiform eruption. Expand
The effect of topical isoprenaline on psoriatic skin
The mean glycogen level was found to be decreased significantly after topical application of 0.1% isoprenaline sulphate ointment and the scaling also disappeared, which may have been due to an increase in the ratio of cyclic AMP/cyclic GMP which inhibited cell turnover and increased glycogenolysis. Expand
Abnormal cell proliferation in psoriasis.
The present study was undertaken to determine whether the cell cycle of individual germinative cells is faster in psoriatic epidermis than normal and if such an acceleration is a significant factor in the pathophysiology of psoriasis. Expand
Adverse reaction to the β‐adrenergic blocking drugs
The last 10 years have seen a rapid increase in the use of drugs which inhibit adrencrgic // receptors, mainly in the cardio-vascular field, and the first of these drugs to gain acceptance was practolol (4-hydroxy-3-isopropylamine propoxy) acetanilide. Expand
Commentary: Cyclic Adenosine Monophosphate Regulation of Normal and Psoriatic Epidermis
If the cAMP hypothesis is a tenable explanation for misregulated epidermal proliferation in psoriasis, it must be compatible with the current understanding of proliferative homeostasis. Expand
Abnormal proliferation of uninvolved psoriatic epidermis: differential induction by saline, propranolol, and tape stripping in vivo.
Uninvolved psoriatic skin appears to possess an abnormal regulation of epidermopoiesis that may be amplified by propranolol injection. Expand
Effects of chronic cetamolol therapy on resting, ambulatory, and exercise blood pressure and heart rate
It is suggested that cetamolol reduces BP without lowering HR at rest, during periods of increased adrenergic activity such as work and dynamic exercise, both HR and BP are reduced. Expand